- Trials with a EudraCT protocol (75)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
75 result(s) found for: Pituitary adenoma.
Displaying page 3 of 4.
EudraCT Number: 2005-003444-53 | Sponsor Protocol Number: CSMS995BIT12 | Start Date*: 2005-10-11 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A randomised, open label, multicenter study comparing the efficacy and safety of medical treatment with Sandostatin LAR 30 mg administered every 21 days for 6 months with that of Sandostatin LAR 60... | |||||||||||||
Medical condition: Treatment of acromegalic patients partially responsive to somatostatin analogues | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000500-83 | Sponsor Protocol Number: 2-55-52060-002 | Start Date*: 2008-07-15 | |||||||||||
Sponsor Name:Ipsen Pharma | |||||||||||||
Full Title: A phase II exploratory, ascending dose, multicentre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability, of BIM23A760 in acromegalic patients. | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) BE (Completed) IT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003741-33 | Sponsor Protocol Number: NRA6290020 | Start Date*: 2007-12-17 | |||||||||||
Sponsor Name:Barts and the London NHS Trust | |||||||||||||
Full Title: A Study To Determine The Optimum Serum IGF-I Range In Patients With Acromegaly Treated With Pegvisomant | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004300-36 | Sponsor Protocol Number: acmed 01 | Start Date*: 2006-02-27 |
Sponsor Name:Plymouth Hospital NHS Trust, R&D dept | ||
Full Title: Use of somatostatin analogue therapy as primary medical treatment of acromegaly | ||
Medical condition: Acromegaly | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004320-21 | Sponsor Protocol Number: C2L-OCT-01 PR-302 | Start Date*: 2007-10-29 | |||||||||||
Sponsor Name:Ambrilia Biopharma Inc. | |||||||||||||
Full Title: OPEN LABEL EXTENSION STUDY EVALUATING THE SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ... | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023827-34 | Sponsor Protocol Number: 1585/10 | Start Date*: 2011-05-02 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: PHASE III CLINICAL TRIAL TO ASSESS THE ADDED ROLE OF 68Ga-DOTANOC PET-CT IN PATIENTS WITH NEUROENDOCRINE TUMORS | |||||||||||||
Medical condition: neuroendocrine tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000161-40 | Sponsor Protocol Number: AdrenalClock | Start Date*: 2022-07-18 |
Sponsor Name:Medical University of Vienna, Division of Endocrinology | ||
Full Title: Investigating cardiometabolic risk factors and changes in chronobiology patterns in patients with autonomous adrenal cortisol secretion | ||
Medical condition: Autonomous cortisol secretion in patients with adrenal adenoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002912-10 | Sponsor Protocol Number: CH-ACM-01 | Start Date*: 2011-08-31 | |||||||||||
Sponsor Name:Chiasma, Inc. | |||||||||||||
Full Title: EFFICACY AND SAFETY OF ORAL OCTREOLIN™ IN PATIENTS WITH ACROMEGALY WHO ARE CURRENTLY RECEIVING PARENTERAL SOMATOSTATIN ANALOGS | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) NL (Completed) GB (Completed) DE (Completed) SK (Completed) PL (Completed) IT (Completed) SI (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003183-31 | Sponsor Protocol Number: DSC/13/2984/05 | Start Date*: 2014-02-25 |
Sponsor Name:ITALFARMACO S.p.A. | ||
Full Title: A Randomized, Multicenter, Phase II study to Investigate Efficacy and Safety of ITF2984 in Acromegalic patients. | ||
Medical condition: Acromegaly | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) IT (Completed) NL (Completed) HU (Completed) ES (Completed) RO (Completed) PL (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004162-41 | Sponsor Protocol Number: C2L-OCT-01 PR-303 | Start Date*: 2007-10-25 | |||||||||||
Sponsor Name:Mallinckrodt Inc. | |||||||||||||
Full Title: SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ACROMEGALIC PATIENTS | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002919-24 | Sponsor Protocol Number: CSMS995BDE16 | Start Date*: 2006-02-09 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A multicenter, single arm, proof of concept study to investigate in a first stage the efficacy of a combination therapy of Sandostatin® LAR® and Cabergoline, optionally followed by a combination of... | |||||||||||||
Medical condition: acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005838-37 | Sponsor Protocol Number: A-38-52030-214 | Start Date*: 2008-05-15 | |||||||||||
Sponsor Name:Beaufour Ipsen Pharma | |||||||||||||
Full Title: A PROSPECTIVE, INTERNATIONAL, MULTI-CENTRIC, OPEN-LABEL STUDY TO ASSESS THE EFFICACY OF AN EXTENDED INJECTION INTERVAL SCHEDULE OF LANREOTIDE AUTOGEL 120 MG IN ACROMEGALIC SUBJECTS WHO ARE BIOCHEMI... | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FR (Completed) DK (Completed) NL (Completed) FI (Completed) LV (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000297-72 | Sponsor Protocol Number: 2-55-52030-727 | Start Date*: 2007-04-24 | |||||||||||
Sponsor Name:BEAUFOUR IPSEN Pharma | |||||||||||||
Full Title: Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and... | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GR (Completed) DE (Completed) CZ (Completed) DK (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002193-31 | Sponsor Protocol Number: CRN00808-05 | Start Date*: 2020-02-19 | |||||||||||
Sponsor Name:Crinetics Pharmaceuticals, Inc. | |||||||||||||
Full Title: AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRN00808 IN SUBJECTS WITH ACROMEGALY (ACROBAT ADVANCE) | |||||||||||||
Medical condition: Acromegaly is typically caused by a growth hormone (GH) secreting tumor in the pituitary. Excess GH secretion results in excess secretion of insulin-like growth factor-1 (IGF-1) from the liver, whi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) SK (Completed) GR (Trial now transitioned) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002133-37 | Sponsor Protocol Number: COR-2012-01 | Start Date*: 2014-11-17 | |||||||||||
Sponsor Name:Cortendo AB | |||||||||||||
Full Title: An Open Label Study to Assess the Safety and Efficacy of COR—003 (2S, 4R-Ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome | |||||||||||||
Medical condition: Endogenous Cushing's syndrome (CS) or Cushing's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) BE (Completed) NL (Completed) SE (Completed) DK (Completed) DE (Completed) IT (Completed) BG (Completed) CZ (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004677-12 | Sponsor Protocol Number: RHYTHM | Start Date*: 2021-02-09 | |||||||||||
Sponsor Name:UNIVERSITA' DEGLI STUDI DI MODENA E REGGIO EMILIA - DIPARTIMENTO DI SCIENZE BIOMEDICHE, METABOLICHE E NEUROSCIENZE | |||||||||||||
Full Title: Pharmacodynamics and safety of human recombinant luteinising hormone in hypogonadotropic hypogonadal men. | |||||||||||||
Medical condition: Aquired hypogonadotropic hypogonadism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001292-51 | Sponsor Protocol Number: CH-ACM-01-FU | Start Date*: 2015-06-30 | |||||||||||
Sponsor Name:Chiasma, Inc. | |||||||||||||
Full Title: Follow-Up Study in Patients with Acromegaly Previously Participating in Chiasma Study CH-ACM-01 | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) SI (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003868-37 | Sponsor Protocol Number: D-FR-10380-002 | Start Date*: 2016-10-06 | ||||||||||||||||
Sponsor Name:Ipsen Pharma SAS | ||||||||||||||||||
Full Title: A phase IIa, open-label, single-arm, two stage, multi-centre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of repeated subcutaneous administration of BIM23B06... | ||||||||||||||||||
Medical condition: Confirmed diagnosis of acromegaly, with or without a history of pituitary surgery, treatment naïve patients or patients that have received prior treatment for their acromegaly. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) BE (Completed) BG (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002854-11 | Sponsor Protocol Number: OOC-ACM-302 | Start Date*: 2016-04-18 | |||||||||||
Sponsor Name:Chiasma, Inc. | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, MULTICENTER STUDY TO EVALUATE MAINTENANCE OF RESPONSE, SAFETY AND PATIENT REPORTED OUTCOMES IN ACROMEGALY PATIENTS TREATED WITH OCTREOTIDE CAPS... | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) RO (Completed) LT (Completed) DE (Completed) NL (Prematurely Ended) ES (Completed) AT (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002190-66 | Sponsor Protocol Number: HS-19-647 | Start Date*: 2019-07-12 | |||||||||||
Sponsor Name:Camurus AB | |||||||||||||
Full Title: A Phase 3, open-label, single-arm, multi-center trial to assess the long term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) ES (Ongoing) GR (Completed) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
